|
1
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith A, Howell D, Patmore R, Jack A and
Roman E: Incidence of haematological malignancy by sub-type: A
report from the Haematological Malignancy Research Network. Br J
Cancer. 105:1684–1692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun Z, Zhang A, Jiang T, Du Z, Che C and
Wang F: MiR-145 suppressed human retinoblastoma cell proliferation
and invasion by targeting ADAM19. Int J Clin Exp Pathol.
8:14521–14527. 2015.PubMed/NCBI
|
|
4
|
Zhou XU, Qi L, Tong S, Cui YU, Chen J,
Huang T, Chen Z and Zu XB: miR-128 downregulation promotes growth
and metastasis of bladder cancer cells and involves VEGF-C
upregulation. Oncol Lett. 10:3183–3190. 2015.PubMed/NCBI
|
|
5
|
Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong
S, Chen W, Yang J and Li H: MiR-1180 promotes apoptotic resistance
to human hepatocellular carcinoma via activation of NF-κB signaling
pathway. Sci Rep. 6:223282016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shih AH, Abdel-Wahab O, Patel JP and
Levine RL: The role of mutations in epigenetic regulators in
myeloid malignancies. Nat Rev Cancer. 12:599–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
White BS and DiPersio JF: Genomic tools in
acute myeloid leukemia: From the bench to the bedside. Cancer.
120:1134–1144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rommer A, Steinleitner K, Hackl H,
Schneckenleithner C, Engelmann M, Scheideler M, Vlatkovic I,
Kralovics R, Cerny-Reiterer S, Valent P, et al: Overexpression of
primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer.
13:3642013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DiNardo CD and Cortes JE: New treatment
for acute myelogenous leukemia. Expert Opin Pharmacother.
16:95–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Copsel S, Bruzzone A, May M, Beyrath J,
Wargon V, Cany J, Russel FG, Shayo C and Davio C: Multidrug
resistance protein 4/ ATP binding cassette transporter 4: A new
potential therapeutic target for acute myeloid leukemia.
Oncotarget. 5:9308–9321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Croce CM: MicroRNA dysregulation in acute
myeloid leukemia. J Clin Oncol. 31:2065–2066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Erdogan B, Bosompem A, Peng D, Han L,
Smith E, Kennedy ME, Alford CE, Wu H, Zhao Z, Mosse CA, et al:
Methylation of promoters of microRNAs and their host genes in
myelodysplastic syndromes. Leuk Lymphoma. 54:2720–2727. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alemdehy MF and Erkeland SJ: MicroRNAs:
Key players of normal and malignant myelopoiesis. Curr Opin
Hematol. 19:261–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vasilatou D, Papageorgiou S, Pappa V,
Papageorgiou E and Dervenoulas J: The role of microRNAs in normal
and malignant hematopoiesis. Eur J Haematol. 84:1–16. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shibayama Y, Kondo T, Ohya H, Fujisawa S,
Teshima T and Iseki K: Upregulation of microRNA-126-5p is
associated with drug resistance to cytarabine and poor prognosis in
AML patients. Oncol Rep. 33:2176–2182. 2015.PubMed/NCBI
|
|
16
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y, Jacamo R, Konopleva M, Garzon R,
Croce C and Andreeff M: CXCR4 downregulation of let-7a drives
chemoresistance in acute myeloid leukemia. J Clin Invest.
123:2395–2407. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X and Zhong H: The diagnosis,
prognosis, and therapeutic application of MicroRNAs in
haematological malignancies. Hematology. 21:263–271. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang XX, Wang Y, Wang PP and Li Y:
Expression of microRNA-148/152 family in the mematological
malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 23:1173–1178.
2015.(In Chinese). PubMed/NCBI
|
|
21
|
Amodio N, Rossi M, Raimondi L, Pitari MR,
Botta C, Tagliaferri P and Tassone P: miR-29s: A family of
epi-miRNAs with therapeutic implications in hematologic
malignancies. Oncotarget. 6:12837–12861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: An overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
23
|
Lo Coco F and Foa R: Diagnostic and
prognostic advances in the immunophenotypic and genetic
characterization of acute leukaemia. Eur J Haematol. 55:1–9. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised
criteria for the classification of acute myeloid leukemia. A report
of the French-American-British cooperative group. Ann Intern Med.
103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak and Schmittgen, . Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo
X, Mao XH, Zou QM, Yu PW, Zuo QF, et al: Plasma microRNAs, miR-223,
miR-21 and miR-218, as novel potential biomarkers for gastric
cancer detection. PLoS One. 7:e416292012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang BS, Luo QZ, Han Y, Li XB, Cao LJ and
Wu LX: microRNA-223 promotes the growth and invasion of
glioblastoma cells by targeting tumor suppressor PAX6. Oncol Rep.
30:2263–2269. 2013.PubMed/NCBI
|
|
28
|
Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M,
Zhu Y, Zhao Q, Dong YW, Shao K, et al: MicroRNA-223 regulates FOXO1
expression and cell proliferation. FEBS Lett. 586:1038–1043. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang
Y, Chen Z, Chen F and Wang D: miR-223 functions as a potent tumor
suppressor of the Lewis lung carcinoma cell line by targeting
insulin-like growth factor-1 receptor and cyclin-dependent kinase
2. Oncol Lett. 6:359–366. 2013.PubMed/NCBI
|
|
30
|
Li J, Guo Y, Liang X, Sun M, Wang G, De W
and Wu W: MicroRNA-223 functions as an oncogene in human gastric
cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol.
138:763–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laios A, O'Toole S, Flavin R, Martin C,
Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al:
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Mol Cancer. 7:352008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karakatsanis A, Papaconstantinou I,
Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of
microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,
miR-221, miR-222, and miR-223 in patients with hepatocellular
carcinoma or intrahepatic cholangiocarcinoma and its prognostic
significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li S, Li Z, Guo F, Qin X, Liu B, Lei Z,
Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates
migration and invasion by targeting Artemin in human esophageal
carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang H, Yan X, Pan Y, Wang Y, Wang N, Li
L, Liu Y, Chen X, Zhang CY, Gu H and Zen K: MicroRNA-223 delivered
by platelet-derived microvesicles promotes lung cancer cell
invasion via targeting tumor suppressor EPB41L3. Mol Cancer.
14:582015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu
Z, Ou-yang S, Wu H, Zhong Z, Yin Z, et al: MiR-223-3p targeting
SEPT6 promotes the biological behavior of prostate cancer. Sci Rep.
4:75462014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou X, Jin W, Jia H, Yan J and Zhang G:
MiR-223 promotes the cisplatin resistance of human gastric cancer
cells via regulating cell cycle by targeting FBXW7. J Exp Clin
Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang L, Zhu J, Zaorsky NG, Deng Y, Wu X,
Liu Y, Liu F, Cai G, Gu W, Shen L and Zhang Z: MicroRNA-223
enhances radiation sensitivity of U87MG cells in vitro and in vivo
by targeting ataxia telangiectasia mutated. Int J Radiat Oncol Biol
Phys. 88:955–960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Inuzuka H, Zhong J, Wan L,
Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of
FBW7 in cancer development and progression. FEBS Lett.
586:1409–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lau AW, Fukushima H and Wei W: The Fbw7
and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.
Front Biosci (Landmark Ed). 17:2197–2212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Welcker M and Clurman BE: FBW7 ubiquitin
ligase: A tumour suppressor at the crossroads of cell division,
growth and differentiation. Nat Rev Cancer. 8:83–93. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Minella AC and Clurman BE: Mechanisms of
tumor suppression by the SCF(Fbw7). Cell Cycle. 4:1356–1359. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yada M, Hatakeyama S, Kamura T, Nishiyama
M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and
Nakayama KI: Phosphorylation-dependent degradation of c-Myc is
mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nateri AS, Riera-Sans L, Da Costa C and
Behrens A: The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK
signaling. Science. 303:1374–1378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Koepp DM, Schaefer LK, Ye X, Keyomarsi K,
Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent
ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.
Science. 294:173–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fryer CJ, White JB and Jones KA:
Mastermind recruits CycC: CDK8 to phosphorylate the Notch ICD and
coordinate activation with turnover. Mol Cell. 16:509–520. 2004.
View Article : Google Scholar : PubMed/NCBI
|
